Jazz doubles down on sleep disorders, putting down $50M cash to pluck Sumitomo drug for the pipeline
Mere weeks after divesting a commercial treatment for excessive daytime sleepiness, Jazz Pharmaceuticals has in-licensed an early-stage program to test a new target for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
